Creating better viral vectors for muscle gene therapy
Official title: Development of optimized adeno-associated viral capsids for muscle gene therapy
Funded at Aavogen, INC. · NIH-10897976 · Data updated 2026-11-12
This study is working on creating special virus particles that can deliver gene therapies directly to muscle tissues, helping people with rare muscle diseases get safer and more effective treatments with fewer side effects.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aavogen, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | August 2, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $134,000 |
| NIH project number | 5R43AR083297-02 |
| Project ID | NIH-10897976 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 21 and older who are affected by rare muscle and neuromuscular diseases.
✕Less likely to help
Patients with non-muscle related conditions or those under 21 years old may not benefit from this research.
What this research studies
This research focuses on developing new adeno-associated viral (AAV) capsids that are specifically designed to target muscle tissues while minimizing harmful effects on the liver. By engineering these capsids, the goal is to enhance the safety and effectiveness of gene therapies for patients with rare muscle and neuromuscular diseases. The approach involves a rational design method that aims to improve muscle specificity and reduce off-target effects, which have been a significant barrier in current therapies. Patients may benefit from more effective treatments with fewer side effects as a result of this innovative work.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective gene therapies for patients with muscle-related diseases.
How similar studies have gone: While other research has explored enhancing muscle tropism, this approach of simultaneously de-targeting the liver is novel and has not been extensively tested.
Where this research is happening
-
Aavogen, INC.
Rockville, United States Active
Researchers
- Principal investigator: Rodgers, Buel — Aavogen, INC.
- Study coordinator: Rodgers, Buel
Related research
Other NIH-funded projects on the same topics.
-
Developing a new gene therapy for treating muscle degeneration in older adults
This study is testing a new gene therapy called AVGN7 to help older adults with sporadic inclusion body myositis (IBM) by boosting muscle strength and function, with hopes of making life easier and more enjoyable for those living with this challenging condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.